BioShield Law Deflects Devices With Commercial Opportunity – Aethlon CEO
This article was originally published in The Gray Sheet
Executive Summary
BioShield requirements related to stockpile purchases of medical countermeasures should be made less restrictive, according to Aethlon Medical CEO James Joyce
You may also be interested in...
Biopreparedness Act of 2005
Product liability provisions in S 3 address perceived shortcomings of Bioshield Act of 2004. The new language, including a noneconomic damages cap of $250,000 - awardable only for physical harm - would benefit manufacturers, distributors and providers of any "equipment, service (including support services), device, or technology (including information technology) designed...for the specific purpose of preventing, detecting, identifying, or preventing a pandemic or epidemic." Introduced Jan. 24 by Sen. Judd Gregg (R-N.H.), the bill was referred to the Finance Committee...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.